No one expects any meaningful script growth in the UK / EU this year . But the market is forward looking . Its main concern IMHO is that AMRN gets UK / EU secondary reimbursements at prices AMRN can make $ on ...with low co pays .....and they maintain a healthy cash on hand to fund that launch in 2023.
Once Denner has the UK / EU reimbursement decisions he will do a DCF analysis ( which U seem to disdain ) and IMHO make the argument that a Co like NVS will generate faster cash flow then AMRN ever will ..in at least the UK / EU .
He'll make that argument to both AMRN and NVS as he did with MDCO / NVS ...I owned MDCO .
Market Data 
Markets 
AI
